Bio Medica Laboratories IPO
Bio Medica Laboratories IPO
Overview
Bio Medica Laboratories IPO is a book build issue of ₹52.43 crores. The issue is a combination of fresh issue of 0.34 crore shares aggregating to ₹47.19 crores and offer for sale of 0.04 crore shares aggregating to ₹5.24 crores. Bio Medica Laboratories IPO opens for subscription on May 21, 2026 and closes on May 25, 2026. The allotment for the Bio Medica Laboratories IPO is expected to be finalized on May 26, 2026. Bio Medica Laboratories IPO will list on the NSE SME with a tentative listing date fixed as May 29, 2026. Bio Medica Laboratories IPO is set issue price band at ₹132 to ₹139 per share. The lot size for an application is 1,000 shares. The minimum amount of investment required by an individual investor (retail) is ₹2,78,000 (2,000 shares) (based on upper price). The minimum lot size for investment in HNI is 3 lots (3,000 shares), amounting to ₹4,17,000. Narnolia Financial Services Ltd. is the book running lead manager and Skyline Financial Services Pvt.Ltd. is the registrar of the issue. The Market Maker of the company is Prabhat Financial Services Ltd.
Issue Size
₹37,72,000
Issue Price
₹52 Cr
Price Band
₹132 – ₹139
Lot Size
1000 shares
Min. Investment
₹1,32,000
Max. Investment
₹1,39,000
Open Date
21 May, 2026
Close Date
25 May, 2026
Allotment
26 May, 2026
Listing
29 May, 2026
Max. Investment
₹1,39,000
Announced
21 May, 2026
Opening Date
21 May, 2026
Closing Date
25 May, 2026
Basis of Allotment
26 May, 2026
Initiation of Refunds
27 May, 2026
Credit of Shares
27 May, 2026
Listing Date
29 May, 2026
Apply via UPI in 5 minutes
Choose your broker • Zero commission on IPO
About Bio Medica Laboratories IPO
Incorporated in August 2015, Bio Medica Laboratories specialises in manufacturing pharmaceutical parenteral formulations, producing a wide range of ethical drugs, generic drugs, and over-the-counter (OTC) medications in liquid and dry-powder injectable forms.der injectables. These injectables are available in both single-dose and multi-dose formats, serving the needs of both human and veterinary healthcare.
Product portfolio:
- Liquid Injectables: 58 products a
Bio Medica Laboratories IPO Share Price
Issue Breakdown
Shareholding
Dilution: 37.0% increase in shares
Bio Medica Laboratories IPO Financial Health
Bio Medica Laboratories IPO Lot Size
Investors can bid for a minimum of 2,000 shares and in multiples of 1,000 shares thereof.
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Individual investors (Retail) (Min) | 2 | 2000 | ₹2,78,000 |
| Individual investors (Retail) (Max) | 2 | 2000 | ₹2,78,000 |
| S-HNI (Min) | 3 | 3000 | ₹4,17,000 |
| S-HNI (Max) | 7 | 7000 | ₹9,73,000 |
| B-HNI (Min) | 8 | 8000 | ₹11,12,000 |
(All values in CR)
Bio Medica Laboratories IPO Valuations
| Metric | Value |
|---|---|
| ROE | 54.41 |
| ROCE | 23.22 |
| Debt/Equity | 2.23 |
| RoNW | 54.41 |
| PAT Margin | 30.35 |
| EBITDA Margin | 47.11 |
| Price to Book Value | - |
(All values in CR)
Bio Medica Laboratories IPO Strength & Risk
Bio Medica Laboratories IPO – Strength
- Operates in the pharmaceutical injectable formulations segment
- Manufactures liquid injections and dry powder injections for human and veterinary use
- Strong growth in revenue and profitability in recent years
- Healthy EBITDA and PAT margins
- Diversified product portfolio across ethical, generic, and OTC medicines
- GMP-certified manufacturing operations
- Supplies products across multiple Indian states
- Experienced promoters and management team
- IPO proceeds planned for manufacturing expansion and debt reduction
- Valuation appears relatively reasonable compared to sector peers
Bio Medica Laboratories IPO – Risk
- SME IPOs carry high volatility and liquidity risk
- Pharmaceutical sector faces strict regulatory and compliance requirements
- Dependence on limited key clients may impact revenue concentration
- Quality control issues can affect brand reputation and operations
- Debt-to-equity ratio remains relatively elevated
- High competition in injectable pharmaceutical market
- Sustained negative cash flow history may impact future growth
- Dependence on a single manufacturing location increases operational risk
- Regulatory non-compliance history may remain a concern
- Large minimum investment size increases retail investor risk
Bio Medica Laboratories IPO GMP
Bio Medica Laboratories SME IPO last GMP is ₹0, last updated May 19th 2026 07:55 AM. With the price band of 139.00, Bio Medica Laboratories SME IPO's estimated listing price is ₹139 (cap price + today's GMP).The expected percentage gain/loss per share is 0.00%.
Last updated 19 May, 2026 · Source: aggregated grey-market dealers
| Date | IPO Price | GMP | Sub2 Sauda | Est. Listing | Est. Profit | Updated |
|---|---|---|---|---|---|---|
| 19 May, 2026 | 139 | ₹0 | - | ₹139 (0.00%) | - | 19 May, 2026 |
| 18 May, 2026 | 139 | ₹0 | - | ₹139 (0.00%) | - | 18 May, 2026 |
| 17 May, 2026 | 0 | ₹0 | - | ₹ (%) | - | 17 May, 2026 |
Disclaimer: GMP is an unofficial signal from grey-market dealers and is not regulated by SEBI. Use it alongside subscription data and other research for informed decision-making.
How to Apply for Bio Medica Laboratories IPO
Login to Your Trading App
Open Zerodha, Upstox, Groww, Angel One, or any brokerage app.
Go to IPO Section
Find Bio Medica Laboratories IPO under the IPO section. Select it and enter your bid details — choose lot size and price (cut-off price recommended).
Enter UPI ID and Submit
Provide your UPI ID linked to your bank account and submit the application.
Approve Mandate on UPI App
Open your UPI app (Google Pay, PhonePe, Paytm, BHIM) and approve the IPO payment request.
Application Confirmed
Your funds will be blocked in your account until the IPO allotment process is completed.